A Bimetallic Metal–Organic‐Framework‐Based Biomimetic Nanoplatform Enhances Anti‐Leukemia Immunity via Synchronizing DNA Demethylation and RNA Hypermethylation
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Epigenetic‐alterations‐mediated antigenicity reducing in leukemic blasts (LBs) is one of the critical mechanisms of immune escape and resistance to T‐cell‐based immunotherapy. Herein, a bimetallic metal–organic framework (MOF)‐based biomimetic nanoplatform (termed as AFMMB) that consists of a DNA hypomethylating agent, a leukemia stem cell (LSC) membrane, and pro‐autophagic peptide is fabricated. These AFMMB particles selectively target not only LBs but also LSCs due to the homing effect and immune compatibility of the LSC membrane, and induce autophagy by binding to the Golgi‐apparatus‐associated protein. The autophagy‐triggered dissolution of AFMMB releases active components, resulting in the restoration of the stimulator of interferon genes pathway by inhibiting DNA methylation, upregulation of major histocompatibility complex class‐I molecules, and induction of RNA‐methylation‐mediated decay of programmed cell death protein ligand transcripts. These dual epigenetic changes eventually enhance T‐cell‐mediated immune response due to increased antigenicity of leukemic cells. AFMMB also can suppress growth and metastases of solid tumor, which was suggestive of a pan‐cancer effect. These findings demonstrate that AFMMB may serve as a promising new nanoplatform for dual epigenetic therapy against cancer and warrants clinical validation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Dynamic RNA Modifications in Gene Expression Regulation
Roundtree, I. A., Evans, M. E., Pan, T., & He, C. (2017) · Cell · doi:10.1016/j.cell.2017.05.045 · Cited by 3,399
RNA modifications modulate gene expression during development
Frye, M., Harada, B. T., Behm, M., & He, C. (2018) · Science · doi:10.1126/science.aau1646 · Cited by 1,249
From Mechanism to Mouse: A Tale of Two Bioorthogonal Reactions
Sletten, E. M., & Bertozzi, C. R. (2011) · Accounts of Chemical Research · doi:10.1021/ar200148z · Cited by 1,093
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O’Laughlin, M., Fulton, R. S., Wilson, R. K., Baty, J. D., Duncavage, E. J., Tandon, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605949 · Cited by 796
Sun, X., Zhang, Y., Li, J., Park, K. S., Han, K., Zhou, X., Xu, Y., Nam, J., Xu, J., Shi, X., et al. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00962-9 · Cited by 788
Short, N. J., Rytting, M. E., & Cortes, J. E. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31041-9 · Cited by 781
Pollyea, D. A., Stevens, B. M., Jones, C. L., Winters, A., Pei, S., Minhajuddin, M., D’Alessandro, A., Culp-Hill, R., Riemondy, K. A., Gillen, A. E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0233-1 · Cited by 778
Targeting FTO Suppresses Cancer Stem Cell Maintenance and Immune Evasion
Su, R., Dong, L., Li, Y., Gao, M., Han, L., Wunderlich, M., Deng, X., Li, H., Huang, Y., Gao, L., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.017 · Cited by 763
Identification of a candidate therapeutic autophagy-inducing peptide
Shoji-Kawata, S., Sumpter, R., Leveno, M., Campbell, G. R., Zou, Z., Kinch, L., Wilkins, A. D., Sun, Q., Pallauf, K., MacDuff, D., et al. (2013) · Nature · doi:10.1038/nature11866 · Cited by 760
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
Yang, S., Wei, J., Cui, Y.-H., Park, G., Shah, P., Deng, Y., Aplin, A. E., Lu, Z., Hwang, S., He, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10669-0 · Cited by 743
Cited by
Quasi Fe MIL-53 nanozyme inducing ferroptosis and immunogenic cell death for cancer immunotherapy
Yan, Z., Bai, Y., Zhang, S., Kong, L., Wang, Y., Sun, H., Li, Y., Qiu, L., Zhang, R., Jiang, P., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57542-x · Cited by 117
“Notably,thespleenofthemice treated with Q-MIL-53(Fe) was smaller compared to the other groups, indicating reduced immune suppression and promoting antitumor immunity 87,88 (Supplementary Fig.”
Self-citationLi, B., Ashrafizadeh, M., & Jiao, T. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.129391 · Cited by 98
Mao, Z., Wang, B., Zhang, T., & Cui, B. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06265-2 · Cited by 55
Nanotherapeutics targeting autophagy regulation for improved cancer therapy
Liu, Y., Wang, Y., Zhang, J., Peng, Q., Wang, X., Xiao, X., & Shi, K. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.019 · Cited by 48
Self-citationYang, Y., Wang, N., Wang, Z., Yan, F., Shi, Z., & Feng, S. (2025) · ACS Nano · doi:10.1021/acsnano.4c12304 · Cited by 48
Self-citationLi, X., Liu, Y., Ke, J., Wang, Z., Han, M., Wang, N., Miao, Q., Shao, B., Zhou, D., Yan, F., et al. (2024) · Advanced Materials · doi:10.1002/adma.202414365 · Cited by 48
Self-citationWang, Z., Han, M., Wang, Y., Wang, N., Yang, Y., Shao, B., Miao, Q., Shi, Z., Yan, F., & Feng, S. (2025) · ACS Nano · doi:10.1021/acsnano.4c15761 · Cited by 47
Self-citationLi, J., Zhao, Q., Zhang, N., Wu, L., Wang, Q., Li, J., Pan, Q., Pu, Y., Luo, K., Gu, Z., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c02337 · Cited by 43
Nanoporous Crystalline Materials for the Recognition and Applications of Nucleic Acids
Yu, L., Wang, Y., Sun, Y., Tang, Y., Xiao, Y., Wu, G., Peng, S., & Zhou, X. (2023) · Advanced Materials · doi:10.1002/adma.202305171 · Cited by 34
Self-citationMetal–organic frameworks: a biomimetic odyssey in cancer theranostics
Soman, S., Kulkarni, S., Kulkarni, J., Dhas, N. L., Roy, A. A., Pokale, R., Mukharya, A., & Mutalik, S. (2025) · Nanoscale · doi:10.1039/d5nr00794a · Cited by 27
Tousian, B., Khosravi, A., Ghasemi, M. H., & Kadkhodaie, M. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101134 · Cited by 25
“Song et al. reported on a bimetallic MOF-based biomimetic nanoplatform that synchronizes DNA demethylation and RNA hypermethylation to enhance anti-leukemia immunity [181].”
BackgroundYu, L., Xu, Q., Sun, Y., Wang, Y., Tang, Y., Yuan, Q., Peng, S., Wu, G., Xiao, Y., & Zhou, X. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c01839 · Cited by 23
Self-citationEnhancing the targeting ability of metal–organic frameworks in cancer therapy and diagnosis
Tong, P., Wang, R., Zhou, Y., Liu, Y., Chen, X., James, T. D., Li, M., & Peng, X. (2026) · Nature Reviews Chemistry · doi:10.1038/s41570-026-00807-w · Cited by 31
Dai, X., Du, Y., Li, Y., & Yan, F. (2023) · Materials Today Bio · doi:10.1016/j.mtbio.2023.100796 · Cited by 29
“Nanomaterials for targeting epigenetic changes in DNA (e.g., 5-methylcytosine) [203], RNA (e.g., N6-methyladenosine) [204 – 206], or protein (e.g., ubiquitination) [207] within cancer cells (named the “ nano-epidrug ” ) could be a promising strategy for enhancing immunotherapy [208].”
Self-citationAdvances in Drug Delivery Systems for the Treatment of Acute Myeloid Leukemia
Wu, X., Wang, F., Yang, X., Gong, Y., Niu, T., Chu, B., Qu, Y., & Qian, Z. (2024) · Small · doi:10.1002/smll.202403409 · Cited by 26
Bimetallic Coordination Polymers: Synthesis and Applications in Biosensing and Biomedicine
Sun, Y., Ma, J., Ahmad, F., Xiao, Y.-L., Guan, J., Shu, T., & Zhang, X. (2024) · Biosensors · doi:10.3390/bios14030117 · Cited by 18
“…the immunological treatment of leukemia Song and co-workers prepared a bimetallic MOF-based nanocomposite (called AFMMB) consisting of DNA hypomethylating agents aza-citidine (AZA), leukemic stem cell (LSC) membranes, and pro-autophagic peptides for the immunological treatment of leukemia [184].”
BackgroundZhao, Y., Pei, L., Liu, B., Mao, Z., Niu, Y., Li, S., Yang, M., Liu, W., Hai, H., Luo, Y., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00950 · Cited by 22
Peng, H., Chang, A., Zhang, H., Xu, X., Wang, W., Zhang, K., Yang, J., Xie, S., Peng, X., Yin, X., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03870-5 · Cited by 17
Gao, T., Fu, S., Quan, X., Sun, J., Jiang, M., & Li, J. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s566173 · Cited by 21
“188 Addressing MYC-mediated radioresistance, Wang et al engineered tungsten-based nanosystems co-loaded with 5-Aza (DNMTi) and ITF-2357 (HDACi) that suppress MYC-driven immunosuppression while enhancing dendritic cell antigen presentation and cytotoxic T-cell infiltration through…”
Maietta, I., González‐Fernández, Á., & Simón‐Vázquez, R. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115638 · Cited by 13
Jung, Y. Y., Ahn, K. S., & Shen, M. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216518 · Cited by 14
Yang, Y., Guo, X., Huang, C., Chen, C., Zhou, Y., Gao, Z., Feng, C., Jiang, S., Deng, X., & Wei, Y. Q. (2024) · Small Structures · doi:10.1002/sstr.202300412 · Cited by 13
Hu, Y., Yu, Q., Li, X., Wang, J., Guo, L., Huang, L., & Gao, W. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202403493 · Cited by 14
Qi, L., Zhang, W., Shi, C., Feng, C., Liu, Z., Li, Z., Fang, F., & Chen, X. S. (2025) · Advanced Materials · doi:10.1002/adma.202505951 · Cited by 11
Li, X., Li, H.-Y., Peng, D., Liu, H., Wu, L. Y., Wang, K.-J., Han, Y., Tang, T., Hu, Z., Peng, J., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c01878 · Cited by 13
Ding, M., Dai, X., Yang, C., Zhang, Z., Wang, Z., Wang, Y., Li, Y., & Yan, F. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c04264 · Cited by 10
Self-citationLiu, Y., Yu, S., Chen, Y., Hú, Z., Fan, L., & Liang, G. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1376955 · Cited by 10
Shang, Y., Han, D., Deng, K., Zhou, H., & Wu, M. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202400649 · Cited by 7
Wang, Z., Ao, J., Lai, X., Liu, G., Meng, Y. F., Zhang, Y., Shi, J., Wu, Y., & Wang, C. (2025) · Nanoscale · doi:10.1039/d4nr04593a · Cited by 7
Self-citationCD4+ T cell membrane-based nanocomposites for enhanced dual epigenetic therapy in psoriasis
Hou, L., Wang, N., Miao, Q., Wang, Z., & Yan, F. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.05.067 · Cited by 7
Self-citationLiu, Y., Zhang, T., Jiao, Y., Li, H., Xie, C., Liu, Y., & Cai, H. (2025) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2025.115003 · Cited by 8
Emerging nanocarriers as advanced delivery tools for the treatment of leukemia
Sen, S., Kumar, N., & Ranjan, O. P. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2466409 · Cited by 6
Yang, Y., Yan, F., & Shi, Z. (2024) · Chemical Research in Chinese Universities · doi:10.1007/s40242-024-4108-3 · Cited by 8
Self-citationWang, Y., Han, Z., Hao, G., Cheng, H., Dai, F., Chen, X., & Shi, B. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-04009-2 · Cited by 5
“In recent years, nanomedicines have drawn considerable interest owing to their capabilities in accurate targeting, minimized side effects, and flexible functional performance [10, 11].”
Self-citationBiomimetic Cell Membrane‐Coated MOFs System for Targeted Cancer Therapy
Wu, Q., Chon, J. S. D., Feng, Y., Liang, K., Li, S., Zhang, C. Y., & Ge, J. (2026) · Advanced Science · doi:10.1002/advs.202521580 · Cited by 11
Wang, Y., Ding, X.-Y., Zhang, F., Xie, X., Chen, Y., Wang, Z., Cai, X., Li, Q., Li, L., Chen, X., et al. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.154568 · Cited by 6
Self-citationRaju, P., Ayubee, M. S., Govindan, L., Subramanian, A., Al‐Hakami, A. M., Chidambaram, K., & Kannaiah, S. (2025) · Journal of Cluster Science · doi:10.1007/s10876-025-02890-3 · Cited by 4
Engineered nanotechnology for epigenetic therapy in cancer treatment
Li, Y., Li, Y., Tan, Y., Cai, Y., Liu, X., Wei, C., Yu, W., Fu, Y., & Cao, H. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.170485 · Cited by 4
Gao, Y., Han, M., Liu, Y., Zheng, S., Li, Y., Sun, Y., & Liu, S. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c18209 · Cited by 3
Self-citationPerspectives on materials: Reality and potential of epigenetic drug nano-delivery
Zhang, Y., Xu, D., Hou, X., Wang, X., Zhao, S., & Jin, X. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.157746 · Cited by 7
Wang, Y., Wang, Z., Han, M., Miao, Q., Shao, B., Wang, N., Wang, J., Li, X., Yan, F., & Feng, S. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202417707 · Cited by 4
Self-citationA Sandwich-like metabolic regulator activated γδ T cells for dual immunotherapy
Hou, H., Chu, X., Cheng, G.-D., Li, Z.-Y., Liu, Y., & Li, S. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114473 · Cited by 2
Biomimetic materials for medical applications
Zhang, Y., Guo, J., Luo, Q., Zhang, X., Fan, C., Feng, S., Luo, J., Fan, Y., Wei, Q., Li, J., et al. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004036 · Cited by 3
“…delivery Bimetallic MOF platforms targeting leukemia stem cells, erythro-cyte-mimetic MOF loaded with epigenetic drugs and oxygen Leukemia [211] HA: Hyaluronic acid; TAT: Trans-Activator of Transcription; BMP-6: Bone Morphogenetic Protein 6; MOF: Metal-organic framework. with…”
Chen, J., & Wang, F. (2026) · Translational Oncology · doi:10.1016/j.tranon.2026.102714 · Cited by 2
“Research indicates that Golgi stress responses can trigger autophagy and apoptosis, alter tumor cell sensitivity to chemo-therapeutic drugs, and drive the emergence of drug-resistant phenotypes [10,11].”
Wang, T., Wang, Y., Zhang, Y., Wu, Y., & Zhu, L. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106507 · Cited by 1
Self-citationNanotechnology based approaches for leukemia therapy
(2024) · Biomedical Letters · doi:10.47262/bl/10.2.20241021 · Cited by 1
Zhang, F., Tian, L., Hu, H., Cao, X., Liu, C., Hu, Z., Sun, Y., Dai, Z., & Zheng, X. (2026) · ACS Applied Nano Materials · doi:10.1021/acsanm.5c05247 · Cited by 1
The application of MOF-based drug delivery systems in tumor immunotherapy
Mi, J., Jiang, X., Yin, M., Wang, Y., Tong, Y., & Zhu, Y. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.115506 · Cited by 2
Self-citationHuang, C., Yu, B., Qiu, W., Cheng, H. B., & Li, S. (2025) · Advanced Therapeutics · doi:10.1002/adtp.202500270
“Yan fabricated a bio-inspired nano platform (AFMMB) based on bimetallic metal–organic frameworks (MOFs) for dual DNA and RNA methylation targeting [176].”
Liu, H., Luo, X., Zhang, X., Chen, Q., Pan, J., Zhou, Z., & Sun, M. (2026) · ACS Nano · doi:10.1021/acsnano.6c05479
Xu, L., Hao, J., Zhao, Y., Wang, Y., Yu, Y., He, C., Niu, Z., Ouyang, D., & Xiang, B. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.049
“…various reactions, such as suppressing DNA methylation and activating RNA methylation-mediated degradation of programmed cell death protein ligand transcripts after autophagy is induced to interfere with the growth and metastasis of leukemic blasts (LBs) that are resistant to immunotherapy 351 .”
Self-citationSaleem, I., Khan, Z. U. H., Khan, A., & El‐Sabban, H. A. (2026) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2026.117175
Zheng, Q., Gu, Y., Su, X., Shen, H., Zhao, F., Zhang, Y., Wu, W., Wang, F., Zhang, Y., Hu, Q., et al. (2026) · Advanced Functional Materials · doi:10.1002/adfm.202527407
Sun, B., Wan, R., Wang, R., Yan, F., & Qiu, S. (2026) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2026.141338
Self-citation
Metadata
- Authors
- Song, Y., Zhang, L., Wang, Y., Han, M., Wang, Z., Wang, N., Shao, B., Li, R., Cao, K., Song, M., Du, Y., & Yan, F.
- Affiliations
- Jilin University (CN)
- Corresponding author
- Yan, Fei
- ORCID
- Venue
- Advanced Materials
- Publisher
- Wiley
- Published
- 2023-03-12
- Volume
- 35
- Issue
- 16
- Pages
- e2210895-e2210895
- ISSN
- 0935-9648 (ISSN-L)
- 1521-4095
- OpenAlex
- W4319657107
- Cited by
- 54
- References
- 43
- Citations by year
- 2026: 12 · 2025: 19 · 2024: 19 · 2023: 4
- FWCI
- 4.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Advanced Materials (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (82170154, 81870117)
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- bimetallic metal-organic frameworks, biomimetic nanoplatform, leukemia, DNA demethylation, RNA methylation, leukemia stem cells, autophagy, Golgi-associated proteins, T cell immunity, immune evasion, epigenetic therapy, MHC class I, antigenicity, nanomedicine
- MeSH terms
- Metal-Organic Frameworks, DNA Demethylation, Humans, RNA, Leukemia, Myeloid, Acute, DNA Methylation, Biomimetics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.